Paclitaxel, carboplatin, and gemcitabine (PCG) versus gemcitabine and vinorelbine (GV) in chemotherapy naive patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase III trial of the Minnie Pearl Cancer Research Network (MPCRN)

Michel E. Kuzur,Dianna Shipley,David R. Spigel,James R. Gray,D. S. Thompson,John D. Hainsworth,James E. Bradof,Charles D. Webb,J. G. Gandhi,A. Beschorner,F. A. Greco

Paclitaxel, carboplatin, and gemcitabine (PCG) versus gemcitabine and vinorelbine (GV) in chemotherapy naive patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase III trial of the Minnie Pearl Cancer Research Network (MPCRN)

2005

Michel E. Kuzur
Dianna Shipley
David R. Spigel
James R. Gray
D. S. Thompson
John D. Hainsworth
James E. Bradof
Charles D. Webb
J. G. Gandhi
A. Beschorner
F. A. Greco

7056 Background: The MPCRN phase III trial comparing the triplet PCG to the non-platinum doublet GV has been completed for pts with advanced NSCLC. Initially, a four-arm randomized trial was done a...

Keywords:

non-small cell lung cancer (NSCLC)
Vinorelbine
Paclitaxel carboplatin
Chemotherapy
Gemcitabine
Oncology
Cancer research
Internal medicine
Medicine
chemotherapy naive
Randomized controlled trial

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations